HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MGC Navigates Regulatory Uncertainty With Cannabis Skin Care

This article was originally published in The Rose Sheet

Executive Summary

US regulations concerning use of cannabinoid CBD in consumer products are complex and hazily defined, representing an additional set of challenges for companies launching CBD-based skin care to an already heavily regulated market. MGC Derma does not expect FDA to come down on its CBD use per se, but the firm's specific product claims could still be subject to scrutiny.

You may also be interested in...



Chilyo Plants CBD Skin Care To Soothe Inflammation From 'Environmental Stress'

Actor and martial arts enthusiast Shedrack Anderson co-founded San Francisco firm Chilyo LP to develop "Environmental Response Skincare" products to repair signs of premature aging with an approach targeting "daily stressors of an uncertain, ever-changing environment." Four-product line launched Feb. 5 comprises Facial Elixir Mist, Face & Neck Crème, Total Eye & Lobe Serum and Muscle Balm.

Lauder/Origins' Hello, Calm Mask: Gateway To Bigger Cannabis Skin-Care Play?

The firm hasn’t been swept up in CBD mania, but its new Origins Hello, Calm mask features hemp seed oil “renowned for helping treat skin concerns like dryness and visible irritation." The $28 product is available now at Sephora.com and Origins' website, with a wider rollout planned for October.

FDA Warns Reviva Labs For Collagen-Building, Anti-Inflammatory Claims

FDA cites Reviva for unapproved drug claims on eight of its products marketed as cosmetics. Included among targeted claims are familiar statements about collagen production, inflammation reduction and other benefits the agency views as structure/function effects. A number of the claims onceivably could be allowed under the revised "cosmetic" definition proposed by the Cosmetic Modernization Amendments of 2015.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019952

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel